



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BioMark Receives the Commercialization Support for Business (CSB) Stream 1 Program

Vancouver, British Columbia – (November 25, 2014) –BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that it has received from the Manitoba’s Ministry of Jobs and Economy a funding grant of \$50,000 under Commercialization Support for Business (CSB) program which is designed for small and medium-sized businesses.

The CBS program helps Manitoba continue to move forward by supporting product and process commercialization and business development in all sectors and all regions of the province. Specifically, this funding proceeds will be focused on expanding freedom to operate opinions, product packaging and sample runs, cross-validation with third parties and market validation studies.

President and CEO Rashid Ahmed says, “We are very pleased and grateful to the government of Manitoba for this financial support as we realize technology commercialization. BioMark licensed the technology invented by Dr. Daniel Sitar at the University of Manitoba in 2006. The University has an equity stake in BioMark. BioMark is committed to delivering on all the key milestones under the application and our goal is to continue our partnership with investments in Manitoba.”

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-282-6567
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.